Biopsy Study for Sculptra (Poly-L-Lactic Acid)

Bausch Health Americas, Inc.14 enrolled

Overview

The primary objective of this study involves research to evaluate new collagen (the elastic fibers that provide skin with its strength and resilience) formation in the skin following injections of Sculptra (Poly-L-Lactic Acid or PLLA). The secondary objectives of the study are to better understand the human skin responses to Sculptra and to assess the safety of Sculptra injections.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Healthy Volunteers

Interventions

Poly-L-Lactic Acid InjectionDEVICE

0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).

Eligibility

Sex: ALLMin age: 35 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * If female, the subject must use appropriate form of birth control. Exclusion Criteria: * History of allergies or an allergic reaction to local numbing medications (e.g., lidocaine, etc.), latex, or silicone. * History of forming large scars following an accident or surgery. * History of any bleeding problems. * Redness, swelling, or signs of infection behind the right or left ear between the area of the earlobe and hairline. * Pimples, rashes, scarring or any other skin changes behind the right or left ear between the area of the earlobe and hairline. * History of any medical problems (for example, heart attack, stroke, diabetes/high blood sugar, hepatitis, human immunodeficiency virus (HIV), severe asthma, rheumatoid arthritis, emphysema, breathing problems). Subjects with high blood pressure or high cholesterol may qualify for the study if there have been no changes in their medications for three (3) months. * History of cancer within five (5) years. * Previous cosmetic surgery or cosmetic procedures affecting the area behind the ear. * Subject who plans to have any facial or ear surgery within the next year. * History of alcohol or drug abuse. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (1)

Sanofi-Aventis Administrative Office

Laval, Canada

Outcomes

Primary Outcomes

Biopsies change from baseline to 6 months after first Sculptra injection in level of Type 1 collagen.

Time frame: 6 months

Secondary Outcomes

Change from baseline in level of Type 1 collagen at 3 months and 12 months

Time frame: 3 and 12 months

Change from baseline in level of Type III collagen at 3 months, 6 months, & 12 months by immunohistochemistry in a central laboratory.

Time frame: 3, 6, and 12 months

Qualitative assessment in degree of change from baseline in Type I collagen at 3 months, 6 months, & 12 months by a pathologist.

Time frame: 3, 6, and 12 months

Degree of inflammation assessed by histology at 3 months, 6 months, and 12 months.

Time frame: 3, 6, and 12 months

Qualitative assessment in degree of change from baseline in Type III collagen at 3 months, 6 months, & 12 months by a pathologist.

Time frame: 3, 6, and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.